www.scmp.com

www.scmp.com
Share

www.scmp.com

 •  January 12

Hua Medicine, a biotechnology firm backed by investors including the investment arm of Fidelity International, plans to spend US$200 million in the next three years to bring its diabetes drug to production and grab 15 per cent of the China market by 2025. To fund the plan, the Shanghai-based firm is arranging its fourth round of private share sale...

www.scmp.com

 •  December 11, 2017

Shares of Genscript Biotech jumped 20 per cent after the company said the government had accepted its application for running clinical trials for its blood cancer treatment. The company, one of the world’s largest providers of gene synthesis services – primarily to university researchers and pharmaceutical firms – had its application for an...

www.scmp.com

 •  November 19, 2017

How innovative are Hong Kong’s organisations? Take Octopus; they have created a humble innovation, Octopus O! ePay. The name is hard to remember, and the app little-used. For another example, look to our bus companies. They have created many apps for checking routes, but it’s necessary to open several to look up alternate routes. Our Transport...

www.scmp.com

 •  May 14, 2017

Investors should play it safe when it comes to Chinese drug makers as the sector is going through a major transition despite buoyant stock prices and positive net profit growth last year, an analyst from US broker Jefferies has warned. China’s pharmaceutical market – the world’s second largest after the US – showed “steady growth” in 2016, with...

www.scmp.com

 •  February 14, 2017

The global pharmaceutical industry spends about US$50 billion a year on research and development. Thanks to its growing expertise in clinical trials, Hong Kong is gearing up to take a larger slice of it. A combination of global regulatory changes and growing local competency has catapulted the city forward. In 2004, 221 clinical trials were...

www.scmp.com

 •  February 14, 2017

Greece has enough medicine to last three to four months and drugmakers said that they would continue supplying the country for now, despite increased financial uncertainty after Greeks rejected austerity terms of a bailout. The pharmaceuticals industry is owed more than €1.1 billion (HK$9.4 billion) by Greek hospitals and the state-run health...

www.scmp.com

 •  February 14, 2017

Japan's health ministry said yesterday it was probing claims falsified data was used in an Alzheimer's disease study involving major drug makers. Health officials said they were questioning researchers after being told false data was used in clinical testing for the US$28 million, government-backed Alzheimer's study, aimed at improving diagnosis of...